



Innovating for  
affordable healthcare

# Shilpa Medicare Limited

**Manufacturers and Exporters of Bulk Drugs**

Shilpa House # 12-6-214/A-1, Hyderabad Road,  
RAICHUR - 584 135, Karnataka, India.

Phone : +91-8532-238704, Fax : +91-8532-238876

CIN No. L85110KA1987PLC008739

E-mail : [info@vbshilpa.com](mailto:info@vbshilpa.com) Website : <http://www.vbshilpa.com>

Dated: 20 April, 2019

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**Mumbai-400 051**

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.  
Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

\*\*\*\*\*

This is to inform you that the Pharmaceutical Research & Development Unit of the Company situated at Modavalasa, Vizianagaram (Dt), Andhra Pradesh region has received U.S FDA Establishment Inspection Report (EIR) with intimation of closure of inspection on 08 Apr 2019.

This R&D site has undergone an inspection by the USFDA during 11 Feb 2019 to 13 Feb 2019, wherein we were issued a Form 483 with 1 (one) observation. Based on our responses and follow up actions, the USFDA has determined the inspection classification of this facility as Voluntary Action Initiated (VAI).

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**

  
**Sushil Bajaj**  
Compliance Officer

